STOCK TITAN

Organogenesis Holdings (ORGO) Stock News, Oct 2025-Apr 2026

ORGO NASDAQ

Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.

Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.

Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) said it completed a Type B meeting with the FDA and received confirmation that the ReNu clinical development program is appropriate for a rolling Biologics License Application (BLA) submission expected by the end of 2025. The program includes two large Phase 3 randomized controlled trials, extensive commercial history, and RMAT designation.

The company plans to initiate a rolling BLA for ReNu before the end of December and said, if approved, ReNu could address knee osteoarthritis pain for millions of patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
none
-
Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) will report first quarter fiscal 2026 results after market close on May 7, 2026. Management will host a conference call and live webcast at 5:00 p.m. Eastern Time the same day to discuss results and provide a corporate update with Q&A.

The live webcast is accessible via the company investor website and will be archived for approximately one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
earnings date
-
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) reported record 2025 results with net product revenue $563.0M and fourth-quarter net product revenue of $225.1M (Q4 2025 vs Q4 2024 +78%). Net income was $37.0M for FY2025 and $43.7M in Q4 2025. Adjusted EBITDA was $98.1M for FY2025 and $84.2M for Q4. As of Dec 31, 2025 the company held $94.3M cash with no outstanding debt. Fiscal 2026 guidance assumes total net revenue $350M–$420M, reflecting an expected near-term revenue decline and recovery later in 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.24%
Tags
Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) will report fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 26, 2026.

Management will host a conference call and live webcast at 5:00 p.m. ET on February 26 to discuss results and provide a corporate update; the webcast will be archived on the company website for about one year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.25%
Tags
earnings date
-
Rhea-AI Summary

Avista Healthcare Partners (ORGO) announced on January 5, 2026 three promotions within its investment team: Ryan Moran and Garrett Lustig were promoted to Partner, and Elaine Tang was promoted to Principal.

The announcement highlights each executive's tenure and background: Moran joined Avista in 2018 with prior roles at Morgan Stanley Capital Partners and Bank of America Merrill Lynch; Lustig joined in 2015 from Centerview Partners; Tang joined in 2022 from Partners Group. Each exec currently serves on multiple portfolio company boards, including Organogenesis (Nasdaq: ORGO) for Lustig.

David Burgstahler, CEO, said the promotions reflect Avista's growth and focus on developing leadership as the firm pursues healthcare investment opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.85%
Tags
none
-
Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) has initiated a rolling submission of a Biologics License Application (BLA) to the FDA for ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee arthritis.

Initial modules were submitted under rolling review with final modules expected in the first half of 2026. Company executives said ReNu, if approved, would be the first non-surgical biologic therapy for knee osteoarthritis across all patients, including the most severe. Knee osteoarthritis is estimated to affect 31.1 million Americans, rising to 34.4 million by 2027, with end-stage management typically a total knee replacement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.09%
Tags
none
Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) announced a successful Type-B meeting with the FDA and confirmation to initiate a rolling BLA submission for ReNu planned before the end of December 2025. The company said ReNu's clinical program—two large Phase 3 randomized controlled trials, a separate 200-patient RCT, extensive commercial history, and RMAT designation—was considered appropriate for BLA submission. Management stated that, if approved, ReNu could address a significant unmet need in knee osteoarthritis, a condition affecting an estimated 31.1 million Americans, projected to reach 34.4 million by 2027.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.04%
Tags
none
-
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) reported Q3 2025 net product revenue of $150.5M, up 31% year-over-year, driven by Advanced Wound Care ($141.5M, +31%) and Surgical & Sports Medicine ($9.0M, +25%). Q3 net income was $21.6M versus $12.3M in Q3 2024; adjusted EBITDA was $30.1M. Nine-month net product revenue declined 5% to $338.0M and the nine-month operating loss was $18.6M. Cash and equivalents were $64.4M at Sept 30, 2025. For FY2025 the company updated guidance to $500.0M–$525.0M in net product revenue and adjusted EBITDA of $45.5M–$68.3M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
44.73%
Tags
-
Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) applauded CMS’s finalization of payment reform for skin substitutes/CTPs under the CY 2026 Physician Fee Schedule announced Nov. 3, 2025.

The company highlighted that CMS finalized FDA classifications and a per centimeter-square payment methodology for both physician office and hospital outpatient settings, and said CMS recognized the clinical differentiation of PMA products, which the company believes will increase access and support higher payment and expanded access for PMA technologies. Organogenesis reiterated its multi-decade leadership and said its evidence-based portfolio positions it well for the skin substitutes market in 2026 and beyond.

The release contains forward-looking statements and cautions that actual outcomes are subject to risks and uncertainties described in the company’s SEC filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none
Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) announced inducement equity awards tied to its newly hired Chief Technology Officer, Michael Catarina, effective October 29, 2025.

The Board granted 82,542 non‑statutory stock options (NSOs) with an exercise price of $4.17 per share and 47,962 restricted stock units (RSUs). Both awards vest in substantially equal annual installments over four years beginning October 20, 2025, subject to continued employment. Although granted outside the 2018 Equity Incentive Plan, the awards are governed by that plan's terms and the related award agreements.

The awards were made as an inducement material to Mr. Catarina’s acceptance of employment pursuant to Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.88%
Tags
none

FAQ

What is the current stock price of Organogenesis Holdings (ORGO)?

Organogenesis Holdings (ORGO) last closed at $0.8532.

What is the market cap of Organogenesis Holdings (ORGO)?

The market cap of Organogenesis Holdings (ORGO) is approximately $110.7M.